Methods and compositions for generating stable transfected cells
Inventors
Wang, Weili • Brady, James P. • Peshwa, Madhusudan V.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Methods and compositions are provided involving high producing cell lines. Embodiments concern efficient methods for screening for such cell lines and for creating such cell lines. These cell lines can be used to create large amounts of protein. To quickly generate large quantity of recombinant proteins or vaccines for both pre-clinical study and clinical trials, almost all drug development will face the same challenging obstacle of rapidly generating a high stable producer. Developing and identifying a stable cell line is a critical part of biopharmaceutical development.
Core Innovation
The invention provides methods for producing a stable mammalian cell line that expresses an exogenous polypeptide. Cells are transfected with an expression construct that comprises a selectable gene and a sequence encoding an exogenous polypeptide, using electroporation, and the transfected cells are then subjected to culture conditions that include a conditionally lethal concentration of the selectable gene agent, such as G418, to select for expression of the selection gene.
The invention further defines stable CHO cell expressing line production in which an expression construct encodes a polypeptide conferring G418 resistance and an exogenous polypeptide. The transfection into CHO cells is performed using a flow electroporation device, followed by selecting transfected CHO cells in media comprising at least 1.6 mg/ml of G418 for at least 6 days, isolating selected transfected CHO cells by limiting dilution to obtain clonal cells, and expanding the isolated cells to produce a stable CHO cell expressing line.
The invention also provides a method for screening for high producing CHO cell lines. After transfecting CHO cells with the expression construct using a flow electroporation device, the cells are selected in media comprising greater than about 1.6 mg/ml of G418 for at least 6 days, isolated by limiting dilution to obtain clonal cells, expanded to produce a stable CHO cell expressing line, and evaluated for production of the exogenous polypeptide.
Claims Coverage
The claims cover three independent methods: producing a stable mammalian cell line expressing an exogenous polypeptide, producing a stable CHO cell expressing line, and screening for high producing CHO cell lines. Across the independent claims, the inventive coverage centers on electroporation, including flow electroporation, expression constructs that include a selectable gene for G418 resistance, a conditionally lethal G418 culture step, and clone isolation by limiting dilution for the CHO-focused methods.
Electroporation-based stable expression with selectable gene and exogenous polypeptide
A method that transfects an expression construct into cells using electroporation, where the expression construct comprises a selectable gene and a sequence encoding an exogenous polypeptide, followed by selecting transfected cells under culture conditions comprising a conditionally lethal concentration of at least 1.6 mg/ml of G418 for at least 6 days.
Flow electroporation for stable CHO cell expressing line with limiting dilution clones
A method for producing a stable CHO cell expressing line by transfecting CHO cells with an expression construct encoding a polypeptide conferring G418 resistance and an exogenous polypeptide using a flow electroporation device, selecting transfected CHO cells in media comprising at least 1.6 mg/ml of G418 for at least 6 days, isolating selected transfected CHO cells by limiting dilution to obtain clonal cells, and expanding isolated transfected CHO cells to produce a stable CHO cell expressing line.
Screening for high producing CHO cell lines using G418 selection and clonal evaluation
A method for screening for high producing CHO cell lines by transfecting CHO cells with an expression construct encoding a polypeptide conferring G418 resistance and an exogenous polypeptide using a flow electroporation device; selecting transfected CHO cells in media comprising greater than about 1.6 mg/ml of G418 for at least 6 days; isolating selected transfected CHO cells by limiting dilution to obtain clonal cells; expanding isolated transfected CHO cells to produce a stable CHO cell expressing line; and evaluating the cells for production of the exogenous polypeptide.
Collectively, the independent claims define electroporation- or flow electroporation-mediated transfection with an expression construct containing a G418 resistance/selectable gene, a conditionally lethal G418 selection culture step with specified thresholds and durations, and, for CHO-focused methods, limiting dilution clonal isolation followed by expansion and evaluation of exogenous polypeptide production.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?